Allogeneic cardiosphere-derived cells for myocardial regeneration: Current progress and recent results

Future Cardiology

Volumn 12, Issue 1, 2016, Pages 87-100

  Kapelios, Chris J ^a   Nanas, John N ^a   Malliaras, Konstantinos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

allogeneic cells; cardiosphere derived cells; cell therapy; heart regeneration; heart repair

Indexed keywords

ALLOTRANSPLANTATION; ANGIOGENESIS; CARDIAC STEM CELL; CARDIOSPHERE DERIVED CELL; CELL DIFFERENTIATION; CELL RENEWAL; CELL SURVIVAL; CLONOGENESIS; CYTOKINE RELEASE; ENGRAFTMENT; EXTRACELLULAR MATRIX; HEART DISEASE; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STROMA CELL; MICROENVIRONMENT; MIXED LYMPHOCYTE REACTION; MUSCLE REGENERATION; MYOCARDIAL REGENERATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE; ANIMAL; CARDIAC MUSCLE CELL; CLINICAL TRIAL (TOPIC); CYTOLOGY; HEART; MESENCHYMAL STEM CELL TRANSPLANTATION; PHYSIOLOGY; REGENERATION; TRANSPLANTATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; HEART; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MYOCYTES, CARDIAC; REGENERATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84953309040     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.15.72     Document Type: Review

References (81)

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385(9963), 117-171 (2015).
2. Malliaras K, Marbán E. Cardiac cell therapy: where weve been, where we are and where we should be headed. Br. Med. Bull. 98, 161-185 (2011).
3. Menasché P, Alfieri O, Janssens S, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 117(9), 1189-1200 (2008).
4. Schächinger V, Erbs S, Elsässer A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 355(12), 1210-1221 (2006).
5. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J. Am. Coll. Cardiol. 61(23), 2329-2338 (2013).
6. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114(6), 763-776 (2003).
7. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised Phase 1 trial. Lancet 379(9819), 895-904 (2012).
8. Smith RR, Barile L, Cho HC, et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 115(7), 896-908 (2007).
9. Malliaras K, Makkar RR, Smith RR, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J. Am. Coll. Cardiol. 63(2), 110-122 (2014).
10. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J. Am. Coll. Cardiol. 54(24), 2277-2286 (2009).
11. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 308(22), 2369-2379 (2012).
12. Ascheim DD, Gelijns AC, Goldstein D, et al. Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. Circulation 129(22), 2287-2296 (2014).
13. Crisostomo V, Casado JG, Baez-Diaz C, Blazquez R, Sanchez-Margallo FM. Allogeneic cardiac stem cell administration for acute myocardial infarction. Expert Rev. Cardiovasc. Ther. 13(3), 285-299 (2015).
14. Karantalis V, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. Circ. Res. 116(8), 1413-1430 (2015).
15. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 8(9), 726-736 (2008).
16. Al-Daccak R, Charron D. Allogenic benefit in stem cell therapy: cardiac repair and regeneration. Tissue Antigens 86(3), 155-162 (2015).
17. Jansen OF, Lorkeers SJ, Eding JE, Vesterinen HM, et al. Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: systematic review and meta-analysis of large animal studies. Circ. Res. 116(1), 80-86 (2015).
18. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I-and class II-mismatched recipient mice. Blood 106(13), 4057-4065 (2005).
19. Badillo AT, Beggs KJ, Javazon EH, Tebbets JC, Flake AW. Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response. Biol. Blood Marrow Transplant. 13(4), 412-422 (2007).
20. Poncelet AJ, Vercruysse J, Saliez A, Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation 83(6), 783-790 (2007).
21. Zangi L, Margalit R, Reich-Zeliger S, et al. Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells 27(11), 2865-2874 (2009).
22. Weil BR, Suzuki G, Leiker MM, Fallavollita JA, Canty JM. Comparative efficacy of intracoronary allogeneic mesenchymal stem cells and cardiosphere-derived cells in swine with hibernating myocardium. Circ. Res. 117(7), 634-644 (2015).
23. Malliaras K, Kreke M, Marbán E. The stuttering progress of cell therapy for heart disease. Clin. Pharmacol. Ther. 90(4), 532-541 (2011).
24. Messina E, De Angelis L, Frati G, et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ. Res. 95, 911-921 (2004).
25. Li TS, Cheng K, Lee ST, et al. Cardiospheres recapitulate a niche-like microenvironment rich in stemness and cell-matrix interactions, rationalizing their enhanced functional potency for myocardial repair. Stem Cells 28(11), 2088-2098 (2010).
26. White AJ, Smith RR, Matsushita S, et al. Intrinsic cardiac origin of human cardiosphere-derived cells. Eur. Heart J. 34(1), 68-75 (2013).
27. Cheng K, Ibrahim A, Hensley MT, et al. Relative roles of CD90 and c-Kit to the regenerative efficacy of cardiosphere-derived cells in humans and in a mouse model of myocardial infarction. J. Am. Heart Assoc. 3(5), e001260 (2014).
28. Chan HH, Meher Homji Z, Gomes RS, et al. Human cardiosphere-derived cells from patients with chronic ischaemic heart disease can be routinely expanded from atrial but not epicardial ventricular biopsies. J. Cardiovasc. Transl. Res. 5(5), 678-687 (2012).
29. Ishigami S, Ohtsuki S, Tarui S, et al. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective Phase 1 controlled trial. Circ. Res. 116(4), 653-664 (2015).
30. Malliaras K, Li TS, Luthringer D, et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 125(1), 100-112 (2012).
31. Chimenti I, Smith RR, Li TS, et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ. Res. 106(5), 971-980 (2010).
32. Li TS, Cheng K, Malliaras K, et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J. Am. Coll. Cardiol. 59(10), 942-953 (2012).
33. Cheng K, Li TS, Malliaras K, Davis DR, Zhang Y, Marbán E. Magnetic targeting enhances engraftment and functional benefit of iron-labeled cardiosphere-derived cells in myocardial infarction. Circ. Res. 106(10), 1570-1581 (2010).
34. Carr CA, Stuckey DJ, Tan JJ, et al. Cardiosphere-derived cells improve function in the infarcted rat heart for at least 16 weeks -an MRI study. PLoS ONE 6(10), e25669 (2011).
35. Mishra R, Vijayan K, Colletti EJ, et al. Characterization and functionality of cardiac progenitor cells in congenital heart patients. Circulation 123(4), 364-373 (2011).
36. Simpson DL, Mishra R, Sharma S, Goh SK, Deshmukh S, Kaushal S. A strong regenerative ability of cardiac stem cells derived from neonatal hearts. Circulation 126(11 Suppl. 1), S46-S53 (2012).
37. Takehara N, Tutsumi Y, Tateishi K, et al. Controlled delivery of basic fibroblast growth factor promotes human cardiosphere derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J. Am. Coll. Cardiol. 52, 1858-1865 (2008).
38. Johnston PV, Sasano T, Mills K, et al. Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation 120(12), 1075-1083 (2009).
39. Lee ST, White AJ, Matsushita S, et al. Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J. Am. Coll. Cardiol. 57(4), 455-465 (2011).
40. Malliaras K, Smith RR, Kanazawa H, et al. Validation of contrast-enhanced magnetic resonance imaging to monitor regenerative efficacy after cell therapy in a porcine model of convalescent myocardial infarction. Circulation 128(25), 2764-2775 (2013).
41. Suzuki G, Weil BR, Leiker MM, et al. Global intracoronary infusion of allogeneic cardiosphere-derived cells improves ventricular function and stimulates endogenous myocyte regeneration throughout the heart in swine with hibernating myocardium. PLoS ONE 9(11), e113009 (2014).
42. Davis DR, Zhang Y, Smith RR, et al. Validation of the cardiosphere method to culture cardiac progenitor cells from myocardial tissue. PLoS ONE 4(9), e7195 (2009).
43. Malliaras K, Zhang Y, Seinfeld J, et al. Cardiomyocyte proliferation and progenitor cell recruitment underlie therapeutic regeneration after myocardial infarction in the adult mouse heart. EMBO Mol. Med. 5(2), 191-209 (2013).
44. Malliaras K, Ibrahim A, Tseliou E, et al. Stimulation of endogenous cardioblasts by exogenous cell therapy after myocardial infarction. EMBO Mol. Med. 6(6), 760-777 (2014).
45. Barile L, Gherghiceanu M, Popescu LM, Moccetti T, Vassalli G. Ultrastructural evidence of exosome secretion by progenitor cells in adult mouse myocardium and adult human cardiospheres. J. Biomed. Biotechnol. 2012, 354605 (2012).
46. Barile L, Lionetti V, Cervio E, et al. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc. Res. 103(4), 530-541 (2014).
47. Ibrahim AG, Cheng K, Marbán E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports 2(5), 606-619 (2014).
48. Naumova AV, Modo M, Moore A, Murry CE, Frank JA. Clinical imaging in regenerative medicine. Nat. Biotechnol. 32(8), 804-818 (2014).
49. Naumova AV, Modo M, Moore A, Frank JA, Murry CE. Response to cardiac regeneration validated. Nat. Biotechnol. 33(6), 587 (2015).
50. Malliaras K, Marbán E. Cardiac regeneration validated. Nat. Biotechnol. 33(6), 587 (2015).
51. Isogai T, Yasunaga H, Matsui H, et al. Hospital volume and cardiac complications of endomyocardial biopsy: a retrospective cohort study of 9508 adult patients using a nationwide inpatient database in Japan. Clin. Cardiol. 38(3), 164-170 (2015).
52. Dimmeler S, Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circ. Res. 102(11), 1319-1330 (2008).
53. Cheng K, Malliaras K, Smith RR, et al. Human cardiosphere-derived cells from advanced heart failure patients exhibit augmented functional potency in myocardial repair. JACC Heart Fail. 2(1), 49-61 (2014).
54. Ruggeri L, Capanni M, Martelli MF, Velardi A. Cellular therapy: exploiting NK cell alloreactivity in transplantation. Curr. Opin. Hematol. 8, 355-359 (2001).
55. Atoui R, Shum-Tim D, Chiu RC. Myocardial regenerative therapy: immunologic basis for the potential universal donor cells. Ann. Thorac. Surg. 86, 327-334 (2008).
56. Lauden L, Boukouaci W, Borlado LR, et al. Allogenicity of human cardiac stem/progenitor cells orchestrated by programmed death ligand 1. Circ. Res. 112(3), 451-464 (2013).
57. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114(6), 763-776 (2003).
58. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
59. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol. Rev. 241(1), 180-205 (2011).
60. Boukouaci W, Lauden L, Siewiera J, et al. Natural killer cell crosstalk with allogeneic human cardiac-derived stem/progenitor cells controls persistence. Cardiovasc. Res. 104(2), 290-302 (2014).
61. Tseliou E, Pollan S, Malliaras K, et al. Allogeneic cardiospheres safely boost cardiac function and attenuate adverse remodeling after myocardial infarction in immunologically mismatched rat strains. J. Am. Coll. Cardiol. 61(10), 1108-1119 (2013).
62. Yee K, Malliaras K, Kanazawa H, et al. Allogeneic cardiospheres delivered via percutaneous transendocardial injection increase viable myocardium, decrease scar size, and attenuate cardiac dilatation in porcine ischemic cardiomyopathy. PLoS ONE 9(12), e113805 (2014).
63. Gallet R, Tseliou E, Dawkins J, et al. Intracoronary delivery of self-assembling heart-derived microtissues (cardiospheres) for prevention of adverse remodeling in a pig model of convalescent myocardial infarction. Circ Cardiovasc. Interv. 8(5), e002391 (2015).
64. Kanazawa H, Tseliou E, Malliaras K, et al. Cellular postconditioning: allogeneic cardiosphere-derived cells reduce infarct size and attenuate microvascular obstruction when administered after reperfusion in pigs with acute myocardial infarction. Circ. Heart Fail. 8(2), 322-332 (2015).
65. Crisostomo V, Baez-Diaz C, Maestre J, et al. Delayed administration of allogeneic cardiac stem cell therapy for acute myocardial infarction could ameliorate adverse remodeling: experimental study in swine. J. Transl. Med. 13(1), 156 (2015).
66. Kajstura J, Cheng W, Reiss K, et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab. Invest. 74(1), 86-107 (1996).
67. Kloner RA, Ganote CE, Jennings RB. The no-reflow phenomenon after temporary coronary occlusion in the dog. J. Clin. Invest. 54(6), 1496-1508 (1974).
68. ClinicalTrials Database: NCT01458405. https://clinicaltrials.gov
69. ClinicalTrials Database: NCT02293603. https://clinicaltrials.gov
70. Makkar R, Schatz R, Traverse J, et al. ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): the one year Phase I results. Circulation 130, A20536 (2014).
71. Malliaras K, Marbán E. Moving beyond surrogate endpoints in cell therapy trials for heart disease. Stem Cells Transl. Med. 3(1), 2-6 (2014).
72. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 367, 113-121 (2006).
73. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 113, 1287-1294 (2006).
74. Tendera M, Wojakowski W, Ruzyo W, et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) trial. Eur. Heart J. 30, 1313-1321 (2009).
75. FDA. www.fda.gov
76. Stastna M, Chimenti I, Marbán E, Van Eyk JE. Identification and functionality of proteomes secreted by rat cardiac stem cells and neonatal cardiomyocytes. Proteomics 10(2), 245-253 (2010).
77. Tarte K, Gaillard J, Lataillade JJ, et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 115, 1549-1553 (2010).
78. Bocelli-Tyndall C, Zajac P, Di Maggio N, et al. Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells. Arthritis Rheum. 62, 3815-3825 (2010).
79. Purandare B, Teklemariam T, Zhao L, Hantash BM. Temporal HLA profiling and immunomodulatory effects of human adult bone marrow-and adipose-derived mesenchymal stem cells. Regen. Med. 9(1), 67-79 (2014).
80. Vacanti V, Kong E, Suzuki G, Sato K, Canty JM, Lee T. Phenotypic changes of adult porcine mesenchymal stem cells induced by prolonged passaging in culture. J. Cell Physiol. 205(2), 194-201 (2005).
81. Lee AY, Lee J, Kim CL, et al. Comparative studies on proliferation, molecular markers and differentiation potential of mesenchymal stem cells from various tissues (adipose, bone marrow, ear skin, abdominal skin, and lung) and maintenance of multipotency during serial passages in miniature pig. Res. Vet Sci. 100, 115-124 (2015).